Plasma protein biosignatures for detection of cardiac allograft vasculopathy.

TitlePlasma protein biosignatures for detection of cardiac allograft vasculopathy.
Publication TypeJournal Article
Year of Publication2013
AuthorsLin, D, Freue, GCohen, Hollander, Z, Mancini, GBJohn, Sasaki, M, Mui, A, Wilson-McManus, J, Ignaszewski, A, Imai, C, Meredith, A, Balshaw, R, Ng, RT, Keown, PA, W McMaster, R, Carere, R, Webb, JG, McManus, BM
Corporate AuthorsBiomarkers in Transplantation Team, Networks of Centres of Excellence, Centres of Excellence for Commercialization and Research-Prevention of Organ Failure Centre of Excellence
JournalJ Heart Lung Transplant
Volume32
Issue7
Pagination723-33
Date Published2013 Jul
ISSN1557-3117
KeywordsBlood Proteins, Female, Heart Transplantation, Humans, Male, Middle Aged, Proteomics, Transplantation, Homologous, Vascular Diseases
Abstract

BACKGROUND: Coronary angiography remains the most widely used tool for routine screening and diagnosis of cardiac allograft vasculopathy (CAV), a major pathologic process that develops in 50% of cardiac transplant recipients beyond the first year after transplant. Given the invasiveness, expense, discomfort, and risk of complications associated with angiography, a minimally invasive alternative that is sensitive and specific would be highly desirable for monitoring CAV in patients.

METHODS: Plasma proteomic analysis using isobaric tags for relative and absolute quantitation-matrix-assisted laser desorption ionization double time-of-flight mass spectrometry was carried out on samples from 40 cardiac transplant patients (10 CAV, 9 non-significant CAV, 21 possible CAV). Presence of CAV was defined as left anterior descending artery diameter stenosis ≥ 40% by digital angiography and quantitatively measured by blinded expert appraisal. Moderated t-test robust-linear models for microarray data were used to identify biomarkers that are significantly differentially expressed between patient samples with CAV and with non-significant CAV. A proteomic panel for diagnosis of CAV was generated using the Elastic Net classification method.

RESULTS: We identified an 18-plasma protein biomarker classifier panel that was able to classify and differentiate patients with angiographically significant CAV from those without significant CAV, with an 80% sensitivity and 89% specificity, while providing insight into the possible underlying immune and non-alloimmune contributory mechanisms of CAV.

CONCLUSION: Our results support of the potential utility of proteomic biomarker panels as a minimally invasive means to identify patients with significant, angiographically detectable coronary artery stenosis in the cardiac allograft, in the context of post-cardiac transplantation monitoring and screening for CAV. The potential biologic significance of the biomarkers identified may also help improve our understanding of CAV pathophysiology.

DOI10.1016/j.healun.2013.04.011
Alternate JournalJ. Heart Lung Transplant.
PubMed ID23796154
Grant List / / Canadian Institutes of Health Research / Canada